Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
Oragenics Inc. (OGEN)
NASDAQ:AMEX Investor Relations:
ir.oragenics.com
Company Research
Source: GlobeNewswire
SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed on March 16, 2026 with the Securities and Exchange Commission, the audited consolidated financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company’s ability to continue as a going concern. See further discussion in footnote 1 to the Company’s consolidated financial statements included in the Company’s Annual Report on Form 10-K. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph. This a
Show less
Read more
Impact Snapshot
Event Time:
OGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGEN alerts
High impacting Oragenics Inc. news events
Weekly update
A roundup of the hottest topics
OGEN
News
- Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation [Yahoo! Finance]Yahoo! Finance
- ORAGENICS FILES ANNUAL REPORT ON FORM 10-K [Yahoo! Finance]Yahoo! Finance
- ORAGENICS FILES ANNUAL REPORT ON FORM 10-KGlobeNewswire
- PRISM BioLab partners with Receptor.AI for molecule discovery [Yahoo! Finance]Yahoo! Finance
- ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION [Yahoo! Finance]Yahoo! Finance
OGEN
Sec Filings
- 3/23/26 - Form EFFECT
- 3/19/26 - Form S-3/A
- 3/16/26 - Form 10-K
- OGEN's page on the SEC website